[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-aneurysm-abdominal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-aneurysm-abdominal":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,49,72,105,129,157,186,206,239,279,305,327,348,377],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100593338","ihub-stent-graft-for-iliac-artery-aneurysms-safety-performance-and-effectiveness-study-100593338",false,"NCT07005141","iHub Stent-Graft for Iliac Artery Aneurysms: Safety, Performance, and Effectiveness Study","iHub no Tratamento de Aneurismas ilíacos: Avaliação da Segurança, Desempenho e Eficácia.","TriHub","Inclusion Criteria: Sign the Informed Consent Form (ICF); Are ≥ 18 years of age;\n\nMeet at least one of the following criteria for iliac artery aneurysm:\n\n1. Common iliac artery aneurysm ≥ 25 mm in diameter;\n2. Aneurysm growth of 5 mm or more within the last six months;\n3. Maximum aneurysm diameter exceeds 1 to 1.5 times the normal arterial segment diameter, that is ≥ 25 mm maximum diameter;\n4. Saccular aneurysm greater than 20 mm;\n5. Abdominal aortic aneurysm with extension into the common iliac arteries of less than 20 mm;\n\nHave a previously implanted aorto-bi-iliac stent-graft with branch diameter between 14 and 16 mm;\n\nHave iliac\u002Ffemoral access vessel morphology compatible with vascular access techniques, placement systems, devices, and\u002For accessories;\n\nAre classified as ASA physical status I to III. ASA IV patients may be included if their life expectancy is greater than one year;\n\nAre able and willing to comply with follow-up requirements during the 360-day post-implant period.\n\n\\-\n\nExclusion Criteria: Pregnant women, women of childbearing potential, or breastfeeding women;\n\nA dissection, rupture, or complex vascular lesion due to trauma;\n\nNeed for emergency surgery;\n\nContraindication to angiography;\n\nDiffuse atherosclerotic disease in any common iliac artery reducing its diameter to \\\u003C 4 mm;\n\nCongenital abnormalities where stent placement would obstruct a major artery. Such abnormalities must be assessed prior to treatment;\n\nUnstable angina;\n\nClass III obesity (BMI ≥ 40 kg\u002Fm²) or other clinical conditions that severely limit radiographic visualization of the aorta;\n\nConnective tissue disease (e.g., Marfan or Ehlers-Danlos syndrome);\n\nHypercoagulable state;\n\nContraindication to anticoagulation therapy;\n\nAcute or chronic renal insufficiency (serum creatinine \\> 2.0 mg\u002FdL);\n\nLife expectancy of less than one year;\n\nPresence of a systemic infection that could increase the risk of endovascular device infection;\n\nKnown sensitivity or allergy to device materials: expanded polytetrafluoroethylene (ePTFE), fluorinated ethylene propylene (FEP), or nickel-titanium (Nitinol).\n\n\\-","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the safety, performance, and Preliminary effectiveness of the iHub endoprosthesis system in treating iliac artery aneurysms in adult patients requiring endovascular repair. The study population includes both male and female adults over 18 years of age who meet the inclusion criteria for endovascular treatment of iliac artery aneurysms.\n\nThe main questions it aims to answer are:\n\nIs the iHub stent-graft system safe for use in patients with iliac artery aneurysms? Does the iHub system demonstrate adequate technical performance and sustained patency over a 12-month follow-up period? Participants will undergo a minimally invasive endovascular procedure to implant the iHub endoprosthesis system. The device is designed to preserve internal iliac artery flow while excluding the aneurysmal segment.\n\nParticipants will:\n\nUndergo pre-screening evaluations including clinical examination, laboratory tests, and imaging (CT angiography and ultrasound).\n\nUndergo endovascular implantation of the iHub device. Attend follow-up visits at 30, 90, 180, and 360 days post-implant to assess clinical outcomes and device performance.",[27,28],"Iliac Aneurysm","Aortic Aneurysm, Abdominal",[30,31,32,33,34,35],"iliac aneurysm","iHub","stentgraft system","endovascular treatment","abdominal aortic aneurysm","EVAR","RECRUITING","2026-06-11",{"date":39,"type":40},"2026-06-15","ACTUAL",{"date":42,"type":40},"2026-05-26",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Archo Medical S.A","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100401142","short-neck-aaa-randomized-trial---esar-and-fevar-socrates-100401142","NCT04503395","ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES","Physician Initiated Trial Investigating ESAR (EVAR Plus Heli-FX EndoAnchors) and FEVAR for the Treatment of Aortic Aneurysms With Short Infrarenal Aortic Neck","SOCRATES","Inclusion Criteria:\n\n* Subject is \\>18 years old\n* Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm\n* Subject is not a candidate for safe, effective and durable standard EVAR due to challenging anatomical criteria as confirmed by the Core Lab screening\n* Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements.\n* Subject has provided written informed consent\n\nCT Angiographic Inclusion Criteria\n\n* Subject meets the other anatomical requirements according to the locally applicable Endurant II\u002FIIs stent graft system, Heli-FX EndoAnchor system, Terumo Fenestrated Anaconda (available in EU only) and\u002For Cook Zenith Fenestrated Graft Instructions for Use\n* Proximal neck length of the aorta within 4-15mm and a minimum circumferential sealing zone of 8mm\n* Aortic neck diameter from 19 to 31mm\n* Infrarenal neck angulation ≤45°\n\nExclusion Criteria:\n\n* Subject is participating in a concurrent study which may confound study results\n* Subject has a life expectancy \\\u003C2 year\n* Subject is female of childbearing potential in whom pregnancy cannot be excluded\n* Subject with eGFR \\\u003C30 mL\u002Fmin\u002Fm2 (KDOQI classification - exclude class IV and above) and or on dialysis\n* Subject with a MI or CVA within 3 months prior to index procedure\n* Subject with known Connective Tissue Disease\n* Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment\n* Subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm\n* Subject requires emergent aneurysm treatment, for example, trauma or rupture\n* Subject has a known hypersensitivity or allergies to study device implant material\n* Subject has an aneurysm that is:\n\n  * Suprarenal, pararenal, or thoracoabdominal\n  * Mycotic\n  * Inflammatory\n  * Pseudoaneurysm\n* Subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential \\>50%\n* Pre-op stenosis of the renal arteries \\> 50%\n* Subject has active infection or history of COVID-19. History of COVID-19 is defined as availability of positive COVID-19 test with sequelae or hospitalization for treatment of COVID-19.",{"count":58,"type":21},204,[24],"The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).",[28],"2026-05-20",{"date":64,"type":40},"2026-05-22",{"date":66,"type":40},"2021-05-21",{"date":68,"type":21},"2032-06-01",{"name":70,"class":47},"FCRE (Foundation for Cardiovascular Research and Education)",33,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100476452","comparison-of-evar-and-esar-for-infrarenal-aortic-aneurysms-with-a-wide-proximal-neck-100476452","NCT05484115","Comparison of EVAR and ESAR for Infrarenal Aortic Aneurysms With a Wide Proximal Neck","Randomized Controlled Clinical Trial on the Application of Heli-FX EndoAnchors in Conjunction With the Endurant II\u002FIIs Endograft in Infrarenal Aortic Aneurysms With a Wide Infrarenal Neck (HERCULES Trial)","HERCULES","Inclusion Criteria:\n\n* Age 18 years or older\n* Provided written informed consent\n* Clinical necessity for treatment of the AAA, according to the current guidelines in the geographies participating\n* Elective repair\n* Eligible anatomy for treatment with the Endurant II\u002FIIs stent graft system and Heli-FX EndoAnchor system according to the IFU of both devices\n* Infrarenal neck diameter ≥ 28 mm and ≤32 mm\n* Proximal neck length ≥10mm\n\nExclusion Criteria:\n\n* Anatomy outside the IFU of the ndurant II\u002FIIs stent graft system and Heli-FX EndoAnchor system\n* Planned use of AUI main body device\n* Patient is participating in another clinical study, potentially conflicting with the outcomes of the current study.\n* Patient with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2 before the intervention\n* Patient's life expectancy \\\u003C2 years as judged by the investigator\n* Patient has a psychiatric or other condition that may interfere with the study\n* Patient has a known allergy to any device component\n* Patients with a systemic infection who may be at increased risk of endovascular graft infection.\n* Patient has a coagulopathy or uncontrolled bleeding disorder\n* Patient has a ruptured, leaking, or mycotic aneurysm\n* Patient is not eligible for standard EVAR\n* Patient had a Cerebro Vascular Accident (CVA) or a myocardial infarction (MI) within the prior three months\n* Patient is pregnant (Female patients of childbearing potential only)\n* Patient has active COVID-19 infection or has been diagnosed with long COVID-19 requiring hospitalization within the 6 months prior to procedure.\n* Patient has previously been treated with stent grafts in the aorto-iliac arteries",{"count":81,"type":21},300,[24],"The HERCULES trial is a Randomized controlled clinical trial designed to prospectively compare endosuture aneurysm repair (ESAR) to standard endovascular aneurysm repair (EVAR) clinical outcomes in treatment of infrarenal abdominal aortic aneurysm (AAA) in subjects having wide proximal aortic neck diameters (≥ 28mm and ≤ 32mm).",[28],[86,87,88,89,90,91,92,93,94],"AAA","Endovascular treatment","Wide proximal neck","EndoAnchors","Infrarenal","EVAR (Endovascular aneurysm repair)","ESAR (Endosuture aneurysm repair)","Endurant II\u002FIIs stent graft system","Heli-FX EndoAnchor system","2026-05-08",{"date":97,"type":40},"2026-05-11",{"date":99,"type":40},"2023-05-26",{"date":101,"type":21},"2033-04",{"name":103,"class":47},"Rijnstate Hospital",36,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":128},"100518370","aaa-shape-pivotal-trial-abdominal-aortic-aneurysm-sac-healing-and-prevention-of-expansion-100518370","NCT06029660","AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion","Inclusion Criteria:\n\n1. ≥18 years of age\n2. A candidate for elective EVAR of an infrarenal fusiform aortic aneurysm ≥5.5 cm in diameter in men and ≥5.0 cm in women;\n3. Thrombus burden (percentage of the AAA sac occupied by thrombus) \\\u003C50%, based on pre-procedure CTA\n4. Maximum Lumen diameter within the AAA sac of ≥40mm.\n5. The predicted minimum number of IMPEDE-FX RapidFill Implants for the subject is ≤200.\n\nExclusion Criteria:\n\nGeneral\n\n1. An inability to provide informed consent.\n2. Enrolled in another clinical study that could interfere with the outcomes being studied in this trial.\n3. Unable or unwilling to comply with study follow-up requirements.\n4. Prisoner or member of other vulnerable population\n\nAnatomical\n\n1. Concomitant iliac artery ectasia or aneurysm\n2. Vascular disease and\u002For anatomy that preclude the safe access and positioning of a catheter to deliver the investigational product into the AAA sac.\n3. Ruptured, leaking, inflammatory or mycotic (infected) aneurysm.\n4. Connective tissue disorder (e.g., Marfan's syndrome)\n5. Aneurysmal disease of the descending thoracic aorta\n6. Excessive calcification at the aortic bifurcation to common\u002Finternal iliac bifurcation, that might lead to access difficulties\n\nEVAR\u002FProcedural\n\n1. Use of aortic stent grafts other than the Gore Excluder AAA Endoprosthesis, Gore Excluder Conformable AAA Endoprosthesis, Cook Zenith Flex AAA Endovascular Graft, Medtronic Endurant II and Endurant IIs Stent Graft, or the Terumo TREO Stent Graft to treat the AAA\n2. Use of an aortic stent graft other than those specified1 for a particular site\n3. Planned use of the chosen stent graft outside its instructions for use (IFU)\n4. Use of fenestrated stent grafts or chimney techniques\n5. Use of the Heli-FX EndoAnchor system\n6. Use of embolic devices other than the investigational product to embolize the AAA sac\n7. Use of embolic products to prophylactically or concomitantly embolize the inferior mesenteric artery, lumbar arteries, renal accessory arteries, or internal iliac arteries\n8. Inability to land the distal-most portion of the EVAR stent graft limbs, including extensions, above the internal iliac arteries\n\nMedical History\u002FConditions\n\n1. Coagulopathy or uncontrolled bleeding disorder\n2. Serum creatinine level \\>2.5 mg\u002FdL\n3. Cerebrovascular accident within 3 months prior to the procedure\n4. Myocardial infarction and\u002For major heart surgery within 3 months prior to the procedure\n5. Atrial fibrillation that is not well rate controlled\n6. Life expectancy of \\\u003C2 years post-procedure\n7. Known hypersensitivity or contraindication to platinum, iridium, or polyurethane.\n8. Have active infection at the time of the index procedure documented by pain, fever, drainage, positive culture, or leukocytosis (WBC \\>11,000\u002Fmm3)\n9. A condition that inhibits radiographic visualization during the implantation procedure\n10. History of allergy to contrast medium that cannot be managed medically, or subject is unable to have a CT with contrast for any reason.\n11. Uncontrolled co-morbid medical condition, including mental health issues, that would adversely affect participation in the trial\n12. Pregnant or lactating female: for females of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the trial",{"count":112,"type":21},180,[24],"To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.",[28],[117],"Abdominal Aortic Aneurysm","2026-05-02",{"date":120,"type":40},"2026-05-06",{"date":122,"type":40},"2024-04-05",{"date":124,"type":21},"2031-06",{"name":126,"class":127},"Shape Memory Medical, Inc.","INDUSTRY",49,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100626645","ai-care-artificial-intelligence-for-cardiovascular-analysis-and-risk-evaluation-100626645","NCT07438327","AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation","AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation - Clinical Evaluation of Aorta Automated Imaging Measurement (Aorta AIM)","AI-CARE","* Adults ≥22 years at time of imaging\n* Studies performed 1 Jan 2016 - 31 August 2025\n* CT imaging of the whole, thoracic, or abdominal aorta, with or without contrast enhancement, acquired with any gating protocol (including non-gated)\n* Slice thickness ≤ 3mm\n* CT imaging in which truncation creates discontinuity within a targeted aortic region, preventing reliable diameter measurement (e.g., cardiac-focused CT acquisitions where an incomplete or absent aortic arch creates discontinuity between the aortic root and the descending thoracic aorta)\n\n  o Partial aortic coverage is not grounds for exclusion. Where truncation affects individual regions, only those specific regions will be excluded from analysis; remaining fully captured regions will be retained for measurement.\n* Metal implants \\\u003C5cm from aorta (e.g. thoracic stent)\n* Prior aortic surgery\n* Severe motion artifacts (e.g. \\>3mm vessel blurring)\n* Congenital aortic anomalies (e.g. coarctation, vascular rings)\n* Post-traumatic aortic repairs\n* The patient opted out of having their data used for medical research before the date of cross-referencing by the site team",true,"22 Years",{"count":140,"type":21},250,"OBSERVATIONAL","This study will test how well an artificial intelligence (AI) software called Aorta AIM measures the size of the aorta (the body's main blood vessel) from CT scans. The aorta can become enlarged over time, which may lead to serious health problems. Doctors need to measure the aorta accurately to monitor patients and decide on treatment.\n\nCurrently, doctors measure the aorta manually on CT scans, which takes time and can vary between different doctors. Aorta AIM is designed to measure the aorta automatically and consistently.\n\nIn this study, researchers will compare Aorta AIM's measurements to those made by experienced radiologists or cardiologists (doctors who specialize in reading medical images). The study will use CT scans that have already been taken as part of routine medical care - no additional scans or procedures are needed.\n\nThe study will include approximately 250 participants across multiple hospitals in Brazil and the United States. Participants will be adults who have had a chest or abdominal CT scan that shows their aorta.\n\nThe main goals are to:\n\n* Check if Aorta AIM measures the aorta as accurately as radiologists\n* See if Aorta AIM can help doctors work more efficiently\n* Evaluate if the software works well in different hospital settings and with different types of patients\n\nThis research may help improve how doctors monitor aortic disease and make treatment decisions in the future. There are no risks to participants since the study only uses existing medical images.",[144,145,146,147],"Aortic Aneurysm","Aortic Aneurysm Abdominal","Aortic Aneurysm and Dissection","Aortic Aneurysm, Thoracoabdominal","2026-03-31",{"date":150,"type":40},"2026-04-06",{"date":148,"type":40},{"date":153,"type":21},"2026-09-05",{"name":155,"class":127},"Aiatella Oy",3,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":172,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":71},"100429696","zenith-fenestrated-clinical-study-100429696","NCT04875429","Zenith® Fenestrated+ Clinical Study","Zenith® Fenestrated+ Endovascular Graft Clinical Study","Include Criteria:\n\n1. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a diameter ≥ 55 mm for males and ≥ 50 mm for females\n2. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a growth rate of ≥ 5 mm in 6 months\n3. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with aortic diameter \\> 2x the normal aortic diameter or saccular aneurysm that warrants treatment in the opinion of the investigator\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 2 years\n3. Pregnant, breast-feeding, or planning to become pregnant within 60 months\n4. Inability or refusal to give informed consent by the patient or legally authorized representative\n5. Unwilling or unable to comply with the follow-up schedule, required clinical assessments, and imaging\n6. Simultaneous participation in another investigation study, unless the patient is at least 30 days beyond the primary endpoint of any previous study",{"count":165,"type":21},105,[24],"The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.\n\nUp to 60 additional subjects may be enrolled in Continued Access phase of the study",[28,169,170,171],"Juxtarenal Aortic Aneurysm","Extent IV Thoracoabdominal","Pararenal Aneurysm",[173,174,175,176],"endovascular","Vascular Diseases","Cardiovascular Diseases","Fenestration","2026-03-19",{"date":179,"type":40},"2026-03-23",{"date":181,"type":40},"2023-12-08",{"date":183,"type":21},"2031-11",{"name":185,"class":127},"Cook Research Incorporated",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":194,"conditions":195,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100320014","clinical-outcomes-of-patients-treated-with-open-surgical-repair-for-complex-aortic-aneurysms-100320014","NCT03446287","Clinical Outcomes of Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms","Inclusion Criteria:\n\nPatients undergoing elective, emergent or urgent OR for CAAs, including:\n\n1. Abdominal aortic aneurysms (AAA) not eligible for endovascular aneurysm repair (EVAR), including 1) Infrarenal AAA with complex aneurysm morphology 2) Short neck infrarenal AAA 3) Juxtarenal AAA 4) Suprarenal AAA\n2. Thoracoabdominal aortic aneurysms (TAAA) (Type I - IV)\n3. Chronic aortic dissections\n\nExclusion Criteria:\n\n1. Patients who refuse to participate the study\n2. Patients age \\\u003C 18 years\n3. Pregnant breastfeeding patients",{"count":193,"type":21},150,"This is a prospective, non-randomized, single center, data collection study of patients treated with open surgical repair (OR) for complex aortic aneurysms (CAAs).",[28],"2026-02-19",{"date":198,"type":40},"2026-02-23",{"date":200,"type":40},"2021-07-16",{"date":202,"type":21},"2026-12",{"name":204,"class":47},"Mayo Clinic",1,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":218,"conditions":219,"keywords":223,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":205},"100513941","phase-4-liposomal-bupivacainebupivacaine-in-rectus-sheath-blocks-versus-ropivacaine-in-rectus-sheath-blocks-and-catheters-100513941","NCT05972018","Liposomal Bupivacaine\u002FBupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters","Liposomal Bupivacaine\u002FBupivacaine A Single-Dose Bilateral Rectus Sheath Blocks Versus Ropivacaine in Bilateral Rectus Sheath Blocks And Catheters With Intermittent Hourly Boluses.","EXODUS","Inclusion Criteria:\n\n1. Patients aged 18-80 years\n2. Patients scheduled for elective vascular surgery with an open mid-abdominal laparotomy incision, including abdominal aortic aneurysm repair surgery (AAA), mesenteric artery bypass surgery, and aortobifemoral bypass surgery for aortic occlusive disease.\n3. Patients who are able to speak and read English\n4. Patients with American Society of Anesthesiology (ASA) physical status score I-IV\n5. Patients who are admitted to the hospital and are incidentally discovered to require any of the aforementioned surgeries, being asymptomatic for vascular issues, and having their surgery scheduled no sooner than three days after admission, are also considered eligible.\n\nExclusion Criteria:\n\n1. Emergency vascular reconstruction surgery., patients admitted to the hospital due to symptoms directly associated with their vascular condition, such as severe abdominal pain or a ruptured aneurysm causing bleeding, will be excluded.\n2. Patients with contraindications to RSB, including but not limited to anatomical abnormality, previous surgical intervention that limits or prevents receiving bilateral RSBs, or infection at the injection site.\n3. History of allergy to local anesthetics.\n4. Weight \\\u003C 40 kg, as a combination of 20 mL of Bupivacaine 0.25% with 30 mL of LB is greater than the maximal dose allowed, given concern for local anesthetic toxicity.\n5. Patients who take long-acting opioid medication, or on continuous opioid use \\> 50 MME per day for at least 30 days within 90 days prior to surgery.\n6. Patients who have chronic pain syndrome with a recent preoperative consultation with the chronic pain service. Also, patients with distant metastatic cancers (e.g. bone, lung, brain) confirmed by CT scan.\n7. Patients with current substance abuse, or history of substance abuse within 3 months, this includes any illicit drugs (not including marijuana) or excessive alcohol consumption as defined as 4 or more drinks per day or 8 or more drinks per week for women and 5 or more drinks per day or 15 or more drinks per week for men.\n8. Lack or refusal to sign the study consent.\n9. Patients who are unable to receive postoperative ropivacaine intermittent boluses within the first 5 days after surgery due to issues with their catheter (such as dislodgement, migration, or kinking) will be excluded from the final analysis.\n10. Patients with a plan to undergo abdominal wall surgery, in addition to the vascular surgery that involves a mid-abdomen incision, such as abdominal wall reconstruction surgery. The additional abdominal wall incisions or interventions might have an impact on the study's pain, opioid, and LOS outcomes.","80 Years",{"count":5,"type":21},[217],"PHASE4","The goal of this pilot study is to compare single shot rectus sheath blocks of liposomal bupivacaine\u002Fbupivacaine mixture to bilateral rectus sheath catheters infused with ropivacaine (standard of care at our facility) in patients undergoing vascular surgery with an open mid-abdominal laparotomy incision. This study will assess the safety and feasibility of this approach compared to standard of care.\n\nParticipants will receive either a single dose of liposomal bupivacaine\u002Fbupivacaine mixture intraoperatively at the end of surgery through bilateral rectus sheath blocks (LB\u002FB group) or the standard of care ropivacaine intraoperatively at the end of surgery through bilateral rectus sheath blocks with the insertion of bilateral RS catheter for continuous ropivacaine infusion plus repeated daily boluses (Catheter group; standard care). They will be assessed for differences in the rate of postoperative complications, resources consumed with each intervention, as well as postoperative pain scores, opioid consumption, hospital and PACU length of stay, patient's satisfaction, and quality of recovery, and hospital length of stay.",[28,220,221,222],"Abdominal Aortic Occlusion","Aortoiliac Occlusive Disease","Aortic Diseases",[224,225,226,227,228,229],"Open abdominal aortic repair surgery","Rectus Sheath Block","Rectus Sheath Block and Catheter","Liposomal Bupivacaine","Exparel","Ropivacaine continuous infusion","2025-08-28",{"date":232,"type":40},"2025-09-03",{"date":234,"type":40},"2023-10-18",{"date":236,"type":21},"2026-12-30",{"name":238,"class":47},"Hartford Hospital",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":264,"overallStatus":270,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":48},"100586678","prophylactic-suture-line-sealing-with-nex-glue-r-eco-in-cardiac-and-vascular-surgery-100586678","NCT06918496","Prophylactic Suture Line Sealing With NE'X Glue R-eco in Cardiac and Vascular Surgery","A Prospective ClinicaL investigatiOn Evaluating Prophylactic Sealing of sUture Lines Using the NE'X Glue R-eco Surgical AdhesivE in Cardiac and (Cardio)Vascular Anastomotic Repair Procedures","CLOSURE","Inclusion Criteria:\n\n* Patient ≥ 18 years of age at study entry.\n* Patient is scheduled for open procedures for surgical placement of a prosthetic or biologic graft (patch) or an allograft for cardiac and (cardio)vascular anastomosis repair. Emergency, transplantation and minimally invasive procedures are excluded. Patients receiving long-term anticoagulation, including antiplatelet agent, are included. Choice of graft is at the discretion of the surgeon.\n* Patient is willing and able to be contacted for up to 3 months (± 14 days) follow-up.\n* Patient or legal representative and investigator signed and dated the informed consent form prior to the index-procedure.\n\nExclusion Criteria:\n\n* Patient has a known hypersensitivity, contraindication, or allergic reaction to albumin or glutaraldehyde.\n* Patient has a history of bleeding diathesis or coagulopathy.\n* Presence of active infection or contamination in the to be grafted area or the vicinity.\n* Known vasculitis in the to be grafted area.\n* Patient takes immune suppressive medication like prednisone resulting in weakening of the vessel wall.\n* Patient is refusing blood transfusion.\n* Patient or legal representative is unable \u002F unwilling to provide informed consent.\n* Patient is unable to comply with the protocol or proposed follow-up visits.\n* Female patient is pregnant, lactating, or planning pregnancy during the clinical investigation.\n* Female participants of childbearing age must agree to use safe contraception (e.g., intrauterine devices, hormonal contraceptives: contraceptive pills, implants, transdermal patches hormonal vaginal devices, injections with prolonged release, abstinence).\n* Patients who are currently enrolled in another clinical study, or have recently participated in a clinical study, that could potentially interfere with the outcomes or introduce bias into the results of the current study (as determined by the investigator). This includes studies involving investigational drugs, medical devices, or other interventions that could impact the safety, efficacy, or scientific integrity of this study.",{"count":248,"type":21},60,[24],"This clinical study aims to evaluate the effectiveness and safety of using NE'X Glue R-eco to seal suture lines. The adhesive will be applied to reduce the risk of suture line bleeding in cardiac or vascular repair surgeries, a prosthetic or biologic graft, patch, or allograft.\n\nThe effectiveness of the adhesive will be assessed after restoring blood flow.",[144,145,252,253,254,255,256,257,258,259,260,261,262,263],"Valve Stenoses, Aortic","Valve Regurgitation, Mitral","Valve Regurgitation, Tricuspid","Aneurysm of Ascending Aorta","Aneurysm Abdominal","Artery Diseases, Peripheral","Ventricular Aneurysm","Coronary Artery Disease","Valve Aortic Regurgitation","Aortic Aneurysms Arch","Aortic Aneurysms Descending","Aortic Aneurysms Thoracoabdominal",[265,266,267,268,269],"prophylactic sealing of suture lines","Surgical glue","cardiac and (cardio)vascular anastomotic repair procedures","grafts","NE'X Glue R-eco surgical adhesive","NOT_YET_RECRUITING","2025-04-08",{"date":273,"type":40},"2025-04-09",{"date":275,"type":21},"2025-06-30",{"date":148,"type":21},{"name":278,"class":127},"Grena Biomed Limited",{"id":280,"slug":281,"hasResults":11,"nctId":282,"briefTitle":283,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":287,"conditions":288,"keywords":290,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":205},"100498798","qol-after-complex-endovascular-aortic-repair-100498798","NCT05774938","QoL After Complex Endovascular Aortic Repair","Inclusion Criteria:\n\n* Men and women.\n* Any age (≥18 years)\n* Planned (elective) endovascular treatment by EVAR, FEVAR or BEVAR.\n* Patients previously treated by EVAR which are planned for an adjunct fenestrated cuff will not be included in the basic analysis, but included and analysed separately.\n\nExclusion Criteria:\n\n* Inability to understand and\u002For respond to the study questionnaires that are in Swedish.\n* Inability to provide an informed consent for participation in the study, orally or in writing (This may be due to linguistic or cognitive limitation).\n* Participation in other ongoing studies concerning quality of life.",{"count":286,"type":21},90,"The goal of this prospective observational cohort study is to compare health related quality of life in patients with abdominal aortic aneurysms treated by either standard or complex EVAR (endovascular aneurysm repair) devices. The main questions it aims to answer are:\n\n* Compare differences between the physical scores from the preoperative to the postoperative settings between patients treated with standard EVAR vs non-standard endovascular aortic repair (F-\u002FBEVAR)\n* To compare long-term physical scores postoperatively between patients treated with standard EVAR vs non-standard endovascular aortic repair (F-\u002FBEVAR) at one year.\n* To explore at which time points (if ever) patients treated with standard-EVAR and nonstandard endovascular aortic repair (F-\u002FBEVAR) have restored or normalized physical scores measured by SF-12, measured at 30 days, 6 months, 1 and 3 years.\n\nParticipants will be asked to fill out forms pre- and postoperatively with regards to health related quality of life.\n\nThe different groups for comparison will be either standard EVAR for infrarenal aortic aneurysms or complex EVAR (fenestrated or branched) for paravisceral aortic aneurysms (PVAAA).",[289,144,28],"Quality of Life",[291,292,293,294,295,296],"Endovascular aneurysm repair","Pararenal aortic aneurysm","Quality of life","Paravisceral aortic aneurysm","Fenestrated endovascular aortic repair","Branched endovascular aortic repair",{"date":298,"type":40},"2025-04-10",{"date":300,"type":40},"2023-02-28",{"date":302,"type":21},"2030-01",{"name":304,"class":47},"Karolinska University Hospital",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":312,"maxAge":4,"enrollmentInfo":313,"targetDuration":315,"studyType":141,"phases":4,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":270,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":4},"100584791","technical-evaluation-and-results-of-the-use-of-treo-modular-aortic-endografts-for-the-treatment-of-abdominal-aortic-aneurysms-100584791","NCT06893952","Technical Evaluation and Results of the Use of TREO® Modular Aortic Endografts for the Treatment of Abdominal Aortic Aneurysms","RegisTREO","Inclusion Criteria:\n\n1. Patient who has confirmed his\u002Fher non-opposition to the use of his\u002Fher data in the study.\n2. Patient aged 45 years or older.\n3. Patient with AAA with one of the following criteria:\n\n   * Maximum diameter ≥50 mm for women and ≥55 mm for men\n   * Rapid growth (≥5 mm in 6 months or ≥10 mm in 12 months)\n   * Unruptured AAA with clinical symptoms of abdominal pain\n4. Adequate anatomy for TREO® stent graft implantation, including:\n\n   * Adequate iliac and femoral arteries for the modular system\n   * Suprarenal angle less than 45 degrees\n   * Infrarenal aortic neck greater than or equal to 10 mm in length with an angle less than 60° and an internal diameter of 17mm-32mm, or an infrarenal aortic neck greater than or equal to 15 mm in length with an angle between 60 and 75° and an internal diameter of 16mm-30mm\n   * Distal iliac sealing distance ≥ 10 mm and an iliac diameter between 8-13 mm or a distal iliac sealing distance ≥ 15 mm and a diameter between 13-21 mm\n5. Ability to follow the entire protocol from 1 to 60 months\n6. Life expectancy greater than 2 years\n\nExclusion Criteria:\n\n1. Patients refusing treatment and follow-up as part of the study\n2. Infected or ruptured aneurysm\n3. Associated aortic lesion (thoracic or thoracoabdominal aneurysm) requiring management\n4. Renal failure defined by creatinine \\> 2.5 mg\u002FdL or patient in pre-dialysis status and impossibility of intervention with use of CO2 injection\n5. New York Heart Association (NYHA) class IV\n6. Aneurysmal, dissected distal implantation zone, or including calcifications and\u002For significant thrombus that could compromise sealing\n7. Tortuous iliac and\u002For femoral access and\u002For including calcified stenosis\n8. Systemic infection that could increase the risk of infection of the endoprosthesis\n9. Pathology of the supporting tissues such as collagenosis (Marfan or Ehler-Danlos, etc.)\n10. Known drug use\n11. Known sensitivity or allergy to the materials to be implanted\n12. Patients contraindicated for antiplatelet treatment\n13. Patients with an uncontrolled hematological disorder or heparin-induced thrombocytopenia\n14. Patients who are pregnant or planning to become pregnant\n15. Patients considered hemodynamically unstable or requiring emergency treatment\n16. Patients with severe arterial disease leading to a negative \"outflow\" that may degrade the permeability of implanted stents\n17. Scheduled hybrid aortic technique (surgical and endovascular)\n18. Patients with complex iliac access outside the manufacturer's indications and recommendations that may lead to procedural failure","45 Years",{"count":314,"type":21},209,"5 Years","This study is a clinical investigation as part of the post-market clinical follow-up of the TREO® abdominal aortic graft in its initial use, French, observational, multicenter, non-randomized, single-arm. Information on patient's health and the implanted device will be collected over a period of 5 consecutive years. The data collected will be analyzed on the technical success and the absence of major events (death, stroke, myocardial infarction, visceral ischemia, paraplegia, respiratory failure, renal failure, intraoperative blood loss, thromboembolic event) and possible reinterventions related to the patient's operation.",[145],"2025-03-18",{"date":320,"type":40},"2025-03-25",{"date":322,"type":21},"2025-04",{"date":324,"type":21},"2031-12",{"name":326,"class":127},"Vascutek Ltd.",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":205},"100553654","phase-2-abdominal-aortic-aneurysm-stabilization-with-truncal-cells-controlled-clinical-trial-with-historical-cohorts-100553654","NCT06488898","Abdominal Aortic Aneurysm Stabilization With Truncal Cells: Controlled Clinical Trial With Historical Cohorts","Inclusion Criteria:\n\n1. Subjects with AAA greater than 5 cm diameter with endovascular treatment indication, analyzed by aortic AngioCT.\n2. Subjects ≥ 18 years at the time of inclusion.\n3. Subjects with a good infrarenal neck for a standard device placement, neither fenestrated nor branched.\n4. Patients with an estimated life expectancy greater than 2 years at the time of inclusion.\n5. Women with childbearing capacity must have a negative pregnancy test at the time of inclusion and must agree to use highly effective contraceptive methods (diaphragms plus spermicide or male condom plus spermicide, oral contraceptive combined with a second method contraceptive implant, injectable contraceptive, permanent intrauterine device, sexual abstinence or partner with vasectomy) during their study participation.\n6. The patient must be able to attend all study visits and comply with all study procedures.\n\nExclusion Criteria:\n\n1. Patients with unresolved neoplasia history or hematologic disease.\n2. Patients with uncontrolled arterial hypertension (≥180\u002F110) at the time of inclusion.\n3. Patients with severe heart failure (New York Heart Association \\[NYHA\\] IV) or ejection fraction \\\u003C20%.\n4. Patients with malignant ventricular arrhythmias\n5. Patients with deep vein thrombosis the last three months\n6. Patient with active sepsis at the time of inclusion\n7. Patients with acute myocardial infarction or stroke in the previous month\n8. Any type of medical or psychiatric illness that, in investigator opinion, could be a reason for exclusion from the study.\n9. Patient with major surgery or severe craniocerebral trauma in the 3 months prior to inclusion in the study.\n10. Administration of any investigational drug at the time of inclusion or in the 3 months prior\n11. Infants or pregnant women\n12. Transplanted patients.",{"count":334,"type":21},8,[336],"PHASE2","Phase IIa, single-center clinical trial compared with historical cohorts to evaluate the preliminary safety and efficacy of an allogeneic adipose tissue-derived mesenchymal stem cells infusion in an aneurysmal sac for the treatment of AAA.",[28],"2024-07-04",{"date":341,"type":40},"2024-07-08",{"date":343,"type":40},"2024-06-13",{"date":345,"type":21},"2025-12-31",{"name":347,"class":47},"Instituto de Investigación Hospital Universitario La Paz",{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":137,"sex":17,"minAge":18,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":364,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":205},"100420431","renal-function-after-stentgraft-treatment-of-abdominal-aortic-aneurysm-100420431","NCT04754659","Renal Function After Stentgraft Treatment Of Abdominal Aortic Aneurysm","Renal Function After Stentgraft Treatment Of Abdominal Aneurysm With Supra- Versus Infrarenal Fixation - a Randomized Clinical Study","RENOFIX","Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* Meet criteria for non-ruptured infrarenal\u002Filiac aneurysm\n* Suitable anatomy for treatment with an approved device (CE-marked) stentgraft according to the manufacturers' instructions for use for AAA.\n* Accepted for treatment with endovascular aortic repair (EVAR) by the participating vascular center.\n\nExclusion Criteria:\n\n* Ongoing or planned dialysis\n* AAA treatment requiring stents or stentgrafts in renal and\u002For visceral arteries\n* Inability to independently complete HRQoL questionnaires due to language barriers\n* Anatomical preconditions that do not allow both types of fixation to be used interchangeably, i.e. very advanced suprarenal tortuosity (\\>60 degrees), advanced suprarenal dilatation or infrarenal thrombus \\>25% of circumference.","90 Years",{"count":358,"type":21},252,[24],"This randomized controlled trial aim to determine the impact on renal function after treatment for infrarenal abdominal aortic aneurysm (AAA) with stentgrafts either with active supra- or infrarenal fixation.",[28,362,363],"Renal Insufficiency","Stent-Graft Thrombosis",[34,365,366],"postoperative renal failure","stentgraft complication","2024-05-05",{"date":369,"type":40},"2024-05-07",{"date":371,"type":40},"2022-12-19",{"date":373,"type":21},"2027-12",{"name":375,"class":376},"Vastra Gotaland Region","OTHER_GOV",{"id":378,"slug":379,"hasResults":11,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":141,"phases":4,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":270,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":396,"leadSponsor":398,"locationsCount":205},"100528553","an-exploratory-study-of-iliac-artery-branch-stent-for-internal-iliac-artery-reconstruction-in-abdominal-aortic-aneurysmiliac-aneurysm-repair-100528553","NCT06162273","An Exploratory Study of Iliac Artery Branch Stent for Internal Iliac Artery Reconstruction in Abdominal Aortic Aneurysm\u002FIliac Aneurysm Repair","Comparing the Efficacy and Safety of IBD Stent of Shenzhen Xianjian Company and IBE Stent of American Gore Company for Reconstruction of Internal Iliac Artery in Abdominal Aortic Aneurysm\u002FIliac Aneurysm Repair","Inclusion Criteria:\n\n1. Patients with iliac aneurysms combined with or without abdominal aortic aneurysms and internal iliac arteries reconstructed with iliac branch stents;\n2. Male or female ≥18 years old, ≤85 years old;\n3. Life expectancy \\> 2 years;\n4. The patient signed the informed consent voluntarily and was able to comply with the treatment plan and complete the follow-up and examination as planned.\n\nExclusion Criteria:\n\n1. Fungal or ruptured aneurysm\n2. Known complications of thoracic aortic aneurysm require interventional treatment\n3. American Association of Anesthesiologists (ASA) Grade V\n4. Creatinine \\> 2.5mg\u002FdL or dialysis patients\n5. NYHA Grade IV heart failure\n6. Intercalation, severe calcification, or anchoring area with thrombosis\n7. Severe curvature or narrowing of the iliac and\u002For femoral arteries, resulting in difficulty in stent delivery\n8. Conduct another device or drug study within 1 year of treatment\n9. Systemic infection\n10. Combined with connective tissue disease\n11. Known history of drug use\n12. Known allergies or allergies to equipment materials","85 Years",{"count":386,"type":21},40,"The purpose of this study is to evaluate the efficacy and safety of IBD stent of Shenzhen Xianjian Company and IBE stent of American Gore company in the treatment of abdominal aortic aneurysm\u002Filiac aneurysm reconstruction of internal iliac artery",[28,27],[390,391,392],"Iliac artery branch stent","Patency rate","Internal iliac artery","2023-12-01",{"date":181,"type":40},{"date":393,"type":21},{"date":397,"type":21},"2026-12-01",{"name":399,"class":47},"RenJi Hospital"]